Drug General Information (ID: DDI51WZHB9)
Drug Name			Antithymocyte immunoglobulin (rabbit)		Drug Info		Deferiprone		Drug Info
Drug Type		Polyclonal antibody				Small molecule
Therapeutic Class		Antiinflammatory Agents				Chelating Agents

Mechanism of Antithymocyte immunoglobulin (rabbit)-Deferiprone Interaction (Severity Level: Major)
Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Antithymocyte immunoglobulin (rabbit)				Deferiprone
Mechanism		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 1
		Factor Name		Myelosuppressive effects
		Factor Description		Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
Mechanism Description		Additive myelosuppressive effects by the combination of Antithymocyte immunoglobulin (rabbit) and Deferiprone

Recommended Action
Management		Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided. Otherwise, close monitoring of absolute neutrophil count (ANC) is recommended if coadministration is required.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.
3	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports."